Accel
Acceleron Pharma (XLRN) got here out with a quarterly lack of $0.44 per share versus the Zacks Consensus Estimate of a lack of $0.32. This compares to lack of $0.75 per share a yr in the past. These figures are adjusted for non-recurring gadgets.
This quarterly report represents an earnings shock of -37.50%. 1 / 4 in the past, it was anticipated that this scientific stage biotech creating protein therapeutics for most cancers and uncommon ailments would submit a lack of $0.81 per share when it really produced a lack of $0.86, delivering a shock of -6.17%.
During the last 4 quarters, the corporate has not been capable of surpass consensus EPS estimates.
Acceleron, which belongs to the Zacks Medical – Biomedical and Genetics trade, posted revenues of $39.34 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 19.82%. This compares to year-ago revenues of $3.82 million. The corporate has topped consensus income estimates 3 times during the last 4 quarters.
…